13 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 7 Not applicable, 3 Phase 1, 3 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Completed 5, Active not recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow GlucaGen: new trials by email Literature Review of GlucaGen trials Research Report on GlucaGen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System Dasiglucagon, GlucaGen - Diabetes Mellitus, Type 1 | Phase 2 | Withdrawn | Inreda Diabetic B.V. | 2023-12-29 | 2024-01-03 | |
| Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes GlucaGen - Type 1 Diabetes, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 10 | 2022-09-21 | 2025-08-29 |
| Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes GlucaGen, Saline - Type 1 Diabetes, Hypoglycemia | Not applicable | Completed | Steno Diabetes Center Copenhagen | 22 | 2021-11-23 | 2023-12-05 |
| Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes insulin human, Epinephrin, Muscle biopsy - Type1diabetes | Not applicable | Unknown | Nordsjaellands Hospital | 60 | 2019-12-16 | 2023-05-03 |
| Phenotypic and Genotypic Characterization of New-onset Type I Diabetes Glucagon - Type1diabetes | Not applicable | Active not recruiting | Université Catholique de Louvain | 98 | 2019-06-15 | 2022-06-28 |
| Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition Glucagon, Esmolol, Physiologic saline - glucagon dummy - Drug Overdose, Overdose of Beta-adrenergic Blocking Drug | Phase 4 | Completed | University Hospital Bispebjerg and Frederiksberg | 10 | 2018-06-01 | 2019-10-17 |
| Hepatic Metabolic Changes in Response to Glucagon Infusion Glucagon, Saline - Non-Alcoholic Fatty Liver Disease, Total Pancreatectomy | Not applicable | Completed | Steno Diabetes Center Copenhagen | 27 | 2018-05-01 | 2019-08-06 |
| A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects Dasiglucagon, GlucaGen, Placebo - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 170 | 2017-12-07 | 2021-06-10 |
| A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus dasiglucagon, GlucaGen - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 112 | 2017-06-28 | 2021-05-04 |
| In Vivo Assessment of Cellular Metabolism in Humans Somatostatin, Glucagon - Normal Cellular Metabolism | Phase 1 | Completed | K. Sreekumaran Nair | 17 | 2016-07-01 | 2022-08-03 |
| Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon ZP4207, GlucaGen - Hypoglycemia | Phase 2 | Completed | Zealand Pharma | 81 | 2016-01-01 | 2016-06-15 |
| Physiologic Response to Glucagon at Varying Insulin Levels Glucagon, Insulin - Type 1 Diabetes Mellitus | Not applicable | Completed | Legacy Health System | 11 | 2011-11-01 | 2016-03-29 |
| Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver Glucagon - Type 1 Diabetes Mellitus | Not applicable | Completed | Legacy Health System | 12 | 2011-01-01 | 2015-05-04 |
| Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone Insulin, Asp(B28)-, Glucagon, Placebo - Type 1 Diabetes | Phase 2 | Completed | Legacy Health System | 14 | 2008-11-01 | 2011-10-07 |
| Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers Glucagen, Mayne Glucagon - Hypoglycemia | Phase 1 | Completed | Hospira, now a wholly owned subsidiary of Pfizer | 28 | 2007-08-01 | 2017-03-20 |
| A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002) MK-0893 10 mg, MK-0893 40 mg, MK-0893 200 mg - Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2005-07-01 | 2015-08-19 |
Diabetes Mellitus, Type 1 (9) · Hypoglycemia (8) · Diabetes Mellitus (5) · Insulin Resistance (3) · Motor Activity (2) · Diabetes Complications (1) · Diabetes Mellitus, Type 2 (1) · Drug Overdose (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Poisoning (1)
Legacy Health System (3) · Steno Diabetes Center Copenhagen (3) · Zealand Pharma (3) · Hospira, now a wholly owned subsidiary of Pfizer (1) · Inreda Diabetic B.V. (1) · K. Sreekumaran Nair (1) · Merck Sharp & Dohme LLC (1) · Nordsjaellands Hospital (1) · University Hospital Bispebjerg and Frederiksberg (1) · Université Catholique de Louvain (1)
United States (6) · Denmark (5) · Germany (3) · Austria (2) · Canada (2) · Belgium (1) · Netherlands (1) · United Kingdom (1)
Christina Sylvest, MSc Pharm (2) · Sissel B Lundemose, MD (2) · W Kenneth Ward, MD (2) · Filip Krag Knop, Prof. (1) · G Laverman, MD (1) · K Sreekumaran Nair (1) · Kasper M Petersen, MD (1) · Stuart Mair (1) · Ulrik Pedersen-Bjergaard, MD,PhD,Prof (1) · William K. Ward, MD (1)
PMID 26341131, PMID 29273578, PMID 33103603, PMID 35239971, PMID 35994729, PMID 38427076
2005 (1), 2019 (1), U24DK100469 (1)